Net income fell 19% to $3.26 billion, weighed down by higher income taxes and interest expense. Breast cancer drug Kisqali posted sales of $1.7 billion, up 43% in constant currencies, while leukemia treatment Scemblix rose 89% to $562 million. Multiple sclerosis drug Kesimpta grew 32% to $1.42 billion, and prostate cancer treatment Pluvicto climbed 43% to $651 million. Novartis reaffirmed its full-year 2026 guidance, forecasting low single-digit net sales growth and a low single-digit decline in core operating income in constant currencies. In July, Novartis agreed to acquire Myricx Bio, a biotechnology company developing antibody-drug conjugates targeting cancer, the company said.